Podcasts about Cart

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.

durée : 00:03:35 - Coupe de France (7e tour) : L'Amiens SC archi-favori à Auby , 7 divisions d'écart ! Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Subscribe to DTC Newsletter - ⁠https://dtcnews.link/signup⁠Welcome to the episode: we've got Jordan Gordon back on the mic — the guy leading email, retention and CRO at Pilot House, with 25 years in ecommerce under his belt.Role‑Based Hook (for DTC growth/marketing audience):For DTC founders & growth marketers scaling from $5M–100M in revenue, this is your CRO check‑list for Q4.Here's what we dig into:Why your headline conversion rate is a shaky metric — and why “direct conversion” gives you better signal.The one page type (your top product page) you can fix in time for Black Friday to move the needle.How to push “bundling and recommendations” tools to unlock +8–30% lift in AOV with zero extra ad spend.The eight choke‑points across homepage → category → PDP → cart/checkout you must optimize right now.Real copy & button tips: How a tiny phrase (“Feel organic again”) can flip the homepage from meh to go‑time.Who this is for: DTC brand leads, ecommerce CRO/optimization folks, retention & growth marketers who already run advertising and now need to tighten the funnel.What to steal:Run quick benchmark: Are you hitting 5‑7% Add‑to‑Cart, ~2% conversion, ~1.25% direct conversion in Shopify?Pick your top 3‑5 PDPs and make them ultra‑fast (under 3s load) using a tool/tech stack like Niche.Install a bundling/recommendation engine (like Rebuy) across the site and measure +8% lift in AOV by pushing “people like you bought this + add it” flows.Timestamps00:00 Highest Leverage CRO Insights for Q402:10 Benchmarking Add-to-Cart and Conversion Rates04:45 Why Direct Conversion Is a Better Signal07:00 Speeding Up PDPs with Niche for Instant Wins10:05 Boosting AOV with Rebuy Bundling13:00 The 8 Critical Website Choke Points15:45 Optimizing Copy Around Key Conversion Areas18:20 Homepage Strategy for High-Volume Traffic21:40 What Big Brands Get Right on Their Homepages24:30 Final Q4 CRO Checklist and Fast WinsHashtags#dtcpodcast #q4ecommerce #cro #conversionrateoptimization #ecommercetips #shopifygrowth #blackfridayprep #aov #d2cbrands #onlinescaling Subscribe to DTC Newsletter - https://dtcnews.link/signupAdvertise on DTC - https://dtcnews.link/advertiseWork with Pilothouse - https://www.pilothouse.co/?utm_source=AKNF559Follow us on Instagram & Twitter - @dtcnewsletterWatch this interview on YouTube - https://dtcnews.link/video

Welcome to another electrifying episode of the Lighting Controls Podcast! This time, we're joined by industry veteran Dave Werry, who brings over a decade of hands-on experience in lighting systems, engineering, and field service. 

Derrota da Seleção frente à Irlanda foi apenas uma má noite ou revela problemas mais profundos na seleção portuguesa? 

Send us a textUnderstanding your Amazon customer journey is crucial for sales growth. Learn how to analyze awareness, consideration, and purchase stages to optimize your strategies with the help of My Amazon Guy's expert insights. Discover the steps you can take to fine-tune your advertising and customer targeting for maximum success.Get your hands on the Ultimate Q4 Playbook for Amazon sellers and crush this holiday season! https://bit.ly/46Wqkm3Book a strategy call to dive deeper into your customer journey analytics and unlock real growth for your brand: https://bit.ly/4jMZtxu#AmazonSales #EcommerceGrowth #CustomerJourney #AmazonAdvertising #brandgrowth Watch these videos on YouTube:Use Brand Analytics to Increase Sales https://www.youtube.com/watch?v=HnUKZXZ9uEk&list=PLDkvNlz8yl_b9RMGmU9XeqkI9D7QDOAI8&index=4Simplify Amazon Listing Compliance https://www.youtube.com/watch?v=ArGPygUCFpk&list=PLDkvNlz8yl_b9RMGmU9XeqkI9D7QDOAI8&index=11-----------------------------------------------Plan your best sales season yet with our 2025 Ecommerce Holiday Playbook: https://bit.ly/4hbygovStop wasting ad spend,download our PPC guide and run campaigns that actually convert: https://bit.ly/4lF0OYXFix what's burying your listings, download the SEO toolkit sellers rely on for rankings: https://bit.ly/3JyMDGoDon't wait for chaos, grab the Amazon Crisis Kit before your traffic or rankings take a hit: https://bit.ly/4maWHn0Timestamps00:00 - Amazon Data & Customer Journey01:10 - Understanding the Amazon Customer Journey Funnel02:20 - Analyzing the Awareness Stage: Key Metrics03:40 - Identifying High Potential Customers in Consideration05:00 - The Importance of Add-to-Cart and Wishlist Data06:15 - How to Optimize Your Amazon Sales Funnel for Better Conversion07:30 - Comparing January vs. March: Key Data Shifts08:45 - Improving New-to-Brand Purchases with Targeted Strategies10:00 - Retargeting Strategies for Repeat Customers on Amazon11:15 - How to Leverage Customer Journey Data to Grow Your Brand----------------------------------------------Follow us:LinkedIn: https://www.linkedin.com/company/28605816/Instagram: https://www.instagram.com/stevenpopemag/Pinterest: https://www.pinterest.com/myamazonguys/Twitter: https://twitter.com/myamazonguySubscribe to the My Amazon Guy podcast: https://podcast.myamazonguy.comApple Podcast: https://podcasts.apple.com/us/podcast/my-amazon-guy/id1501974229Spotify: https://open.spotify.com/show/4A5ASHGGfr6s4wWNQIqyVwSupport the show

In this week's episode, associate editor Dr. James Griffin interviews researchers Dr. John Semple and Dr. Othman Al-Sawaf on their groundbreaking studies on transfusion-related acute lung injury and chronic lymphocytic leukemia treatment. Dr. Semple explored how mitochondrial DNA could act as a first hit in lung injury, while Dr. Al-Sawaf revealed that patient fitness may not significantly impact the efficacy of targeted CLL treatments. Both studies challenge existing medical assumptions and suggest new approaches to understanding disease mechanisms and treatment responses.Featured ArticlesThe impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLMitochondrial DNA via recipient TLR9 acts as a potent first-hit in murine transfusion-related acute lung injury (TRALI)

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute. He also serves as Network Director for the Center of Excellence for Multiple Myeloma, and he is an internationally recognized expert in the field of multiple myeloma. Today, we will be discussing the article titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Thank you for speaking with us, Professor Jagannath. Dr. Sundar Jagannath: Thank you for having me, Dr. Davide Soldato. It is a pleasure to be here. JCO is a highly recognized journal among the oncologists, so I am very happy and privileged to be here today. Dr. Davide Soldato: Thank you so much for being with us. So, I wanted to start a little bit with the rationale of the study and the population that was included in the study. So, the trial that we are discussing, CARTITUDE-1, was already published before, and we observed very good results with a single infusion of cilta-cel. So we had previously reported a median progression-free survival of 30 months, and median overall survival was not reached. So, I just wanted to ask you if you could guide us a little bit into the population that was included in the study and also explain a little bit to our listeners what is the drug that we are discussing, cilta-cel. Dr. Sundar Jagannath: It is a CAR T-cell. This is a patient's own lymphocytes, which goes through apheresis and is sent to the company, where they modify it and introduce the B cell receptor. In this case, you know, there is a heavy chain gene receptor for the BCMA, and in cilta-cel, there are actually two receptor sites on each molecule, or there are two binding domains on each receptor molecule. So, it is considered to be quite efficacious. As you reported, the earlier results that the patients who participated, 97% of the patient responded. Now, you asked about the patients who participated in the clinical trial. This clinical trial was conducted between July of 2018 and October of 2019. At that time, this was a phase 1b/phase 2 trial, and the whole idea was to take patients who had relapsed all the available treatment regimen so that these patients were considered to have, in the unmet medical need situation. So, what does that entail? That means the patient should have been exposed to a proteasome inhibitor, to an immunomodulatory molecule, and to an anti-CD38 monoclonal antibody and should have received at least three or more prior lines of therapy and should be actually progressing on their last line of therapy. So with that requirement, if you look at it, the median number of prior therapy on the patients who participated was actually six. So patients were heavily pretreated. They had exhausted all available treatment options. So, they can participate in this clinical trial. And if not, there have been real-world evidence, such as LocoMMotion, which had reported what is the outcome for such a patient if they were treated outside of this clinical trial, if they were treated with the then available regimen. Their median progression free survival would have been only 3 months, and most patients would have lost their life within a year. So, this was truly an unmet medical need with patients in a very difficult clinical situation. Let's put it that way. So, those were the patients who participated in this particular trial. Dr. Davide Soldato: Thank you very much. And as we mentioned before, the results that were obtained in this clinical trial were really very interesting. And now, in this issue of the Journal of Clinical Oncology, you are reporting data with a longer follow up. So we are actually at more than 5 years of follow up for the patients included in this trial. So, I just wanted a little bit of insight into why you decided to report these long-term outcomes and what type of information do you think you could provide with this study to the medical community? Dr. Sundar Jagannath: This is very important because this was a clinical trial that was done in patients who were, as I said, in unmet medical need. Most of the patients had prior stem cell transplantation, had gone through a proteasome inhibitor. Many of them have had both Velcade and carfilzomib treatment. Most of them had been exposed to lenalidomide and pomalidomide. And as required, all of the patients had to have had prior exposure to anti-CD38 monoclonal antibody or daratumumab. So, the patients were heavily pretreated. Typically, TIL CAR T-cells came into the field at this particular moment, until then, we were developing small molecules, and they usually would have a PFS of 3 months and median life expectancy of a year, the overall response rate of 30%, and that is how, if you look back, that is how carfilzomib was approved, that is how pomalidomide was approved. So, the drugs which were approved, including daratumumab, you know, the response rate was in the same ballpark. So you would see that most agents, single agents, would have had a response rate in the neighborhood of 30%, the progression-free survival would have been between 3 to 5 months or 6 months at the most, and the life expectancy was short. And here comes a drug, and when I was following the patients at Mount Sinai, I found that there were a subset of patients, they got one-time treatment and they were in complete remission, no trace of cancer with annual evaluation with PET CT and bone marrow evaluation for MRD. So, I said this is remarkable, and this needs to be reported. And I went to the Janssen and company, and they agreed to review the entire experience. This is remarkable that 32 of the 97 patients, or one third of the patients, were alive and progression-free. This is unheard of for any clinical trial until now, that the patient will be progression-free, one third of the patients on a clinical trial will be progression-free, in the late stage of their disease. So that is the most important impact. And that is why this 5-year follow-up results were presented. Dr. Davide Soldato: Thank you very much. That was very clear. And as you said, we are speaking about a population that was heavily pretreated, that had exhausted all type of treatment options outside of a clinical trial. And as you said, one third of the patients was alive and progression-free after 5 years from being included and infused inside of the study. So, considering this population that, as we said, had received all treatment options, I was wondering if you observed any kind of differences in terms of disease characteristics when looking at these patients that had exceptional response, so, alive and progression-free at 5 years, and the patients that sadly had developed a progression after the infusion in the study. Dr. Sundar Jagannath: This is very important because we wanted to see who are the patients who are having this exceptional outcome. And we looked at all the 97 patients. If we look at all the patients, we saw that there were initially, out of the 97, 17 patients died earlier in the disease course due to treatment related complications, etc. But there were about 46 patients who had progression of disease and 32 patients, or one third, were alive without progression of disease. Then we looked at the 46 patients who had progression of disease. Of them, we found that 30 had disease progression and its complication, and there were actually 13 patients who were still alive even after progression of disease. So we decided to compare these 46 patients who had progression of disease versus 32 patients who had no progression of disease to see what is the difference. To our surprise, the age was similar, male, female distribution was similar. High-risk cytogenetics, which we would have thought, you know, that is why we say high-risk disease, the term, high-risk cytogenetics was equally distributed. That was really a surprise. Number of lines of prior therapy, number of exposure to drugs, all of that was the same. So that was also interesting. But a theme did emerge. Patients, in general, tend to have lower burden of disease who had the exceptional outcome. But there is one which we considered as bad, the extramedullary disease. Multiple myeloma being a blood cancer, it is usually in the bone marrow. When it starts growing outside of the bone marrow, the extramedullary disease, usually it portends poor prognosis. But we were surprised that actually there were an equal number of extramedullary disease patients even in the long-term survivor as those who had progressed of disease. So the most important takeaway was patients who had lower burden of disease, they had less number of myeloma cells in their bone marrow, percentage wise, and the soluble BCMA level was lower. Soluble BCMA is an indirect measure of the amount of plasma cells in the patient's body. It is like a tumor burden. So they were low. So, this was an important finding because it has future ramification, as you can understand. If this treatment is made available earlier in the disease course of the patients, where we are able to control the disease better, then more patients are likely to have such wonderful outcomes as one third of the patient experience in the late stage of the disease. Dr. Davide Soldato: So, you already mentioned soluble BCMA as a marker of potentially better prognosis as being correlated to a lower volume of disease. I was wondering if you could give us some more information about the biomarkers that you evaluated in the study. For example, you evaluated a little bit the CAR T expansion kinetics and also some others that I think could be interesting and could point to some population that experienced such important benefit. Dr. Sundar Jagannath: That is a very important point because CAR T-cell, it is a live cell and its efficacy depends upon how well the CAR T-cell is going to function. And then, you know, the patient undergoes apheresis. This is a patient's own lymphocyte. So first and foremost is who would generate good CAR T-cell. Those who have plenty of lymphocytes at the time they are coming for apheresis. This is likely to happen earlier in the course of the disease than in patients who have gone through numerous lines of therapy and exhausted. So, in this particular trial, of course this was in late stage of the disease, and so we were able to show patients who had lower number of T cell in circulation, and the way to measure is if they had more neutrophils and less lymphocytes. So that is what is called as a higher T cell over neutrophil, they did better. If they have more neutrophil than T cells, then they did not do well. So, procurement. The second one is also whether the T cells are more naive, you know, not exhausted T cells. So more naive T cells, if you are able to procure from the patient, they did very well. Now, after the CAR T-cell manufacture, then the expansion, when you put it back into the patient, if the T cells expand very well, so that the effector, that is the CAR T-cells to the tumor ratio is good, so there are more effector cells, the CAR T was able to expand and the amount of tumor was less, then the efficacy was very, very good. As I said, the patients in this group, those who had a lower burden of disease, they did better, and that is because of the CAR T-cell expansion, so the effector to the target ratio was favorable. So that is another important. And then there are also the type of CAR T-cells, having CD4 T cells with central memory phenotype at the peak expansion also makes a difference. So all of that matters. But this is important because the efficacy of the CAR T-cell, it is persistent, long persistent and keeping the cancer down. Its ability to get rid of the cancer completely at the first go around because usually we are not able to detect the CAR T-cells beyond 6 months in the majority of patients and very rarely after a year or two. So it is very uncommon to find the CAR T-cells in circulation or even in the regular bone marrow evaluation. So, efficacy, the expansion, having naive T cells, having good effector to target ratio and more central memory kind of T cell, because if it is all effector T cell, they will get quickly utilized and get exhausted, whereas the central memory cells can expand more and give more effective CAR T-cells. Dr. Davide Soldato: Thank you very much. I was wondering if you could guide us a little bit into what is your opinion regarding the positioning of CAR T-cells given all of these logistics that is necessary compared, for example, with bispecific antibodies against BCMA, which have the same target, but they do not have all of these logistics before being administered to the patient. Dr. Sundar Jagannath: That is a very important question, how to sequence these treatments now that we have two BCMA-directed CAR T-cells available. We have three BCMA-directed bispecific and one GPRC5D-directed bispecific antibodies are available. And so the question comes in for at least the currently approved CAR T-cell therapy, there is an obligatory time. You have to go through apheresis and you have to ship to the company, and there is a manufacturing time, roughly about 2 months before they can receive it. During that time, you want to make sure the patient's disease is under control. So that is a given. There are several ways to look at it when we evaluate the patient and talk to the patient. One good thing is now the two CAR T-cells which are approved, one is cilta-cel we talked about, and the other one is ide-cel. Ide-cel is approved in earlier line of therapy, two or more prior lines of therapy, and cilta-cel is approved in patients who have failed one line of therapy and who are lenalidomide refractory. So, the treatment of CAR T-cell is available earlier. And as I said, when you administer CAR T-cell earlier, you are able to keep the disease burden down, and it is a one and done deal. There is a better quality of life for the patient, and you are able to produce long, durable remission and potentially a cure. Now coming to the bispecific, they are currently available in later lines of therapy. So if you look at it from a patient's perspective, you can use the CAR T-cell earlier and then go through the bispecific therapy. But if the patient comes with relapsed refractory myeloma and has not used the CAR T-cell therapy and has not used the bispecific therapy, then the physicians have to decide which one they want to use. If somebody's disease is rapidly progressing and they need immediate tumor reduction and they have already exhausted all available therapy, then going through BCMA bispecific therapy is quite appropriate. And secondly, CAR T-cell therapy is generally given to somewhat physically more fit patients, whereas bispecific therapy, because you are giving antibody at step-wise dosing in this patient, and you have the ability to stop at any particular dose and then come back and redose, whereas CAR T is, you just give it to them one time, you have a lot more control. So intermediate frail or even frail patients can go through bispecific therapy, whereas it would not be in the best interest of the patient to go through a CAR T-cell therapy when they are frail. So that is another important point. But from the information available, when the patient goes on a BCMA bispecific therapy and they start progressing on treatment, usually it is their T cells are exhausted or the BCMA is no longer expressed on the tumor cells. So coming with CAR T-cell later on is usually not effective, whereas giving CAR T-cell earlier, if the patient relapses later, they have good T-cell function and most of the time the BCMA is still expressed. So you are able to give the BCMA to the maximum benefit by using the CAR T first and BCMA later. So if somebody asked me how to sequence this, just off the bat, you will say CAR T first, BCMA bispecific second. But as I said, there are unique situations. Then there is another potential that is happening. You can change the target. You can use a BCMA against GPRC5D to reduce the tumor, and then go ahead and consolidate it with a CAR T-cell therapy. That is also possible. You are changing the target from GPRC5D to BCMA, the tumor is already down, so the patient is likely to benefit. So these are all newer treatment options which have become available to the physician. So they will have to look at individual patients and decide what is the best course of action for that patient. Dr. Davide Soldato: So, I just wanted to close a little bit with your opinion about how these results translate into clinical practice. So considering this outstanding 5-year data that we have seen, one third of the patients who are alive and progression-free after a single infusion of cilta-cel, do you think that we could start to think about functional cure even in patients who have a diagnosis of relapsed refractory multiple myeloma? Dr. Sundar Jagannath: My feeling is this is important because in this particular study which is published, 12 patients who were followed at Mount Sinai out of the 32 patients who are alive and progression-free, 12 were followed at Mount Sinai. And they were evaluated every year with bone marrow MRD testing by clonoSEQ in 11 of the 12 patients, and one was by multiparametric flow cytometry. So most of them were 10 to the minus 6, not even one in a million cancer cells, and all of them had functional imaging, which is called PET CT every year. So these were patients who had no evidence of disease that we could detect with the technology available today, serologically, in the bone marrow, or anywhere else in the body with a PET CT. They were found to be disease free after a single infusion of cilta-cel. So, that would be almost to the definition of a cure because if you look at cure as a definition for any cancer, cure is defined as a state of complete remission with no trace of cancer that persists over a period of 5 years or longer without maintenance. And that will be applicable for breast cancer, lymphoma, leukemia. So it is a general statement. And if we use that in myeloma too, then I could say that these 12 patients from my center, we proved that they are cured of their myeloma. They are not functionally cured. You've got to remember, there is only cure. That was the definition across all diseases. So there is nothing like a functional cure. They are cured of myeloma. So is myeloma curable? This is the first time we are looking at that. We do know, every physician treating myeloma that there are patients out there, 10 year and beyond, without evidence of disease. This has been published by University of Arkansas, Bart Barlogie's group, who has been saying that myeloma is a curable disease for a long time. And many others have shown long-term follow up. But this one in a late stage disease, we were able to show that they were one treatment with no maintenance. All other studies have been in newly diagnosed myeloma patients. Nobody has shown in late relapse patients on a clinical trial a third of the patient will be progression-free. And 12 of them who were studied were actually disease free. So they were cured of the disease. So if we accept that, then the next question is, first step towards cure is achieving complete remission. They should have no monoclonal protein by any technology you want to use, no measurable residual disease using next gen sequencing or clonoSEQ, and functional imaging whole body PET CT or whole body MRI. So that is important, definition of the complete remission. And then it has to be sustained. That is something the IMWG and IMS, International Myeloma Society, they will have to come together for a consensus. How many years should they be followed and should be in this kind of status with no trace of cancer? Is it, 3 years are enough? 4 years enough? 5 years is enough? For me, I said in this paper, 5 years is a good definition for achieving a potential cure. Then you use the term 'functionally cured'. I have a problem with functionally cured and operationally cured or whatever. Functionally cured was originally put out by Paiva from Spain. There were 8% of newly diagnosed myeloma patients who have, after they go get treated, they will have an MGUS like phenomenon, a small amount of paraprotein detectable, and they are only 8%. And he said that these patients could be off treatment and the disease does not progress. But the problem is when you are giving treatment like maintenance therapy continuously until progression, you do not know exactly who is in the MGUS situation. So you have to have done sophisticated flow cytometry like Paiva did, and it is not quite clinically applicable. So functionally cured applies only for 8% of the people, so it should go out of the vocabulary. Then you can say 'operationally cured'. These are the patients traditionally Bart Barlogie and others showed that they have a large number of patients who have been followed for 10 years with no recurrence of disease, not on treatment. But in those days, they did not have MRD PET CT and all of them done systematically. So that is why they had to come up with a situation where they said they were operationally cured. So yes, myeloma patients have been cured since auto transplant was introduced. I completely agree. It is not new to the CAR T-cell therapy. But the beauty of the CAR T-cell therapy was it was in relapsed refractory myeloma, unmet medical need, number one. Number two, they were studied systematically. It was a clinical trial adjudicated by FDA and EMA for drug approval, cilta-cel was approved. So these patients were carefully followed, and it was a multi-center study. And in that group of patients, we were able to show patients- So, I think this would indicate cure is a reality in myeloma, and as these kind of treatments, immunologic treatment, either it is a CAR T-cell therapy or BCMA bispecific or whatever, there is a chance more patients are likely to be cured, and these treatments have to move forward and so that we are looking towards a cure. That is the beauty of it, and I just thank you for asking and also throwing in this so-called functionally cured, which people like to use casually, and I say it is time to talk more cure and not stuck with functionally cured because that does not allow the field to progress. Dr. Davide Soldato: Thank you very much. That was very interesting. Dr. Sundar Jagannath: And provocative. Dr. Davide Soldato: A little bit, but I think that we needed to close the podcast with this kind of reflection coming from someone who is an expert in the field, as you are. So, I really wanted to thank you for joining us today and for sharing more on your article, which is titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. Dr. Sundar Jagannath: Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Pedro Henriques sublinha que a equipa de arbitragem e o VAR tomaram uma boa decisão ao expulsar o capitão da seleção portuguesa. Dá nota 6, uma arbitragem positiva.See omnystudio.com/listener for privacy information.

Pedro Henriques sublinha que a equipa de arbitragem e o VAR tomaram uma boa decisão ao expulsar o capitão da seleção portuguesa. Dá nota 6, uma arbitragem positiva.See omnystudio.com/listener for privacy information.

Do the 2001 Patriots compare to the 2025 Patriots in significant ways? // Former Patriots' QB Brian Hoyer joins, says Pats are the real deal // Comparing Maye to Brady //

Editor-in-Chief of Molecular Therapy, Dr. Joseph Glorioso, is joined by Rachael Nimmo, PhD, former director of the Cell Technology Group at Oxford Biomedica, and Kyriacos Mitrophanous, PhD, Chief Innovation Officer at Oxford Biomedica, to discuss an article recently published in Molecular Therapy by Nimmo and colleagues titled “Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector.” Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

HOUR 4: ARE THE CART CORRALS AFFIXED OR NOT AFFIXED?! That is the question. full 2118 Mon, 10 Nov 2025 23:00:00 +0000 BYpLLrNBGkJzXjHRjldrmzcuuqbqEygf news The Dana & Parks Podcast news HOUR 4: ARE THE CART CORRALS AFFIXED OR NOT AFFIXED?! That is the question. You wanted it... Now here it is! Listen to each hour of the Dana & Parks Show whenever and wherever you want! © 2025 Audacy, Inc. News False https://player.am

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML). Join us as we delve into: • An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. • Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias. • Unique side effects associated with each TKI and strategies for dose optimization. • The importance of patient education and monitoring to ensure effective management of side effects. Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care! #CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine

Memory chip stocks like SanDisk (SNDK), Seagate (STX) and Western Digital (WDC) gathered more bullish traction from firms like Loop Capital and Barclays. Diane King Hall explains where the Street is seeing more upside for these companies and the role A.I. plays in their theses. Healthcare stocks dipped after President Trump made comments against health insurers on Truth Social. Diane later turns to Instacart's parent company, Maplebear (CART), which delivered a double-win in earnings through a beat and share buyback announcement.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Join Dr. Adam Brockman as he reveals the hidden power of your grocery cart in shaping your health and longevity. Discover the quiet revolution in functional foods that not only satisfy your cravings but also enhance your well-being. From the clean label movement to personalized nutrition, learn how to make informed choices that can add years to your life. It's time to take control of your health—one shopping trip at a time!Special Guest: Daniel Scharff, Founder of Startup CPG

Na Conversa com Zé Márcio, o economista-chefe da Genial Investimentos, José Márcio Camargo, recebe José Roberto Mendonça de Barros, da MB Associados, para uma análise afiada dos impasses econômicos que desafiam Brasil e mundo. A escalada tarifária nos EUA, o risco de bolha nas gigantes de tecnologia e os dilemas do FED se cruzam com a queda da inflação brasileira, puxada pela supersafra, e o alerta fiscal em ano pré-eleitoral. Um episódio para quem quer entender o que está por trás dos números.DIRETO AO PONTO0:00 — Cartão Black Genial Investimentos0:44 — Apresentação e boas-vindas1:03 — Revisão da política comercial de Trump e do cenário internacional2:49 — Reação do mercado e risco de reajuste dos ativos (Magníficas Sete)4:11 — O impacto do aumento de tarifas na inflação americana6:02 — Contradições na economia dos EUA e o dilema do Fed8:15 — Risco de bolha financeira e ciclos tecnológicos10:22 — Inflação e crescimento: o efeito contraintuitivo das tarifas12:26 — O impulso do setor de tecnologia e o repasse tardio da inflação13:45 — Inflação estrutural e a dificuldade do Banco Central americano15:51 — Sustentabilidade dos valuations do setor de tecnologia (Asset Heavy Status)17:41 — Consequências da desvalorização do dólar para o Brasil19:43 — Fatores de queda da inflação brasileira (externos e internos)21:41 — O efeito da supersafra agrícola na desinflação24:40 — Decisão do Copom e o debate: queda de juros em janeiro ou março?26:42 — Aperto financeiro nas empresas e a crise de RJs no agronegócio28:17 — A grande preocupação com a política fiscal expansionista31:31 — Programas fiscais para 2024 e antecipação da sucessão presidencial33:36 — Cenário pós-eleitoral: dívida elevada e o improvável ajuste fiscal38:04 — Encerramento e agradecimentos

00:00: ☀️ Bom dia Tech!01:12: ⚡ OpenAI pede apoio do governo dos EUA para acelerar construção de data centers de IA02:35:

Invités : - Rodolphe Cart, journaliste et auteur de Mélenchon, le bruit et la fureur : Portrait d'un révolutionnaire aux éditions La Nouvelle Librairie  - Alexandre Malafaye, fondateur du think tank Synopia  - Jean-Michel Salvator, chroniqueur politique et communiquant Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Sonhos videntes, cartoes perdidos e pantufas

Drafting players based on their week 1 performances! A top 25 twinvestigation! Bold predictions for this weekend's marquee matchups! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Scottish Psalter | Richard Sibbes | Forgetting by Tim Schaufert | The Baker's Cart by Jean Michelin | Find more at www.ryanbush.org

In this latest episode of Wellness Junkies, we're diving into our newest product crushes - all tested, tried, and totally worth it. We're so excited to be back sharing the things we're genuinely loving lately. From viral TikTok finds to everyday staples that actually make a difference, this episode is all about the products helping us feel (and look) our best right now.We've been testing everything we talk about for at least three months, so these aren't just first impressions - they're real results from products that earned a spot in our routines. Expect honest reviews, fun discoveries, and a few surprises along the way.If you're in the mood for a little inspiration (and maybe a few new favorites), grab your matcha and tune in, because we did the testing so you don't have to. We hope you love this Product Junkies episode as much as we loved recording it - and maybe find a new favorite (or two) to add to cart.Brands/Mentions + Shop this episode: Shop here ⁠⁠⁠⁠⁠⁠For More on this Episode: Read the full show notes ⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠Join the community:Follow us ⁠⁠⁠⁠⁠@wellnessjunkiesofficial ⁠⁠⁠⁠⁠on InstagramSubscribe to our newsletterShop this episode + our faves on ⁠⁠⁠⁠⁠ShopMyShop⁠⁠⁠⁠⁠NEW! Follow us @wellnessjunkies on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠ and TikTokFollow Amy @amynicolle on TikTokVisit ⁠www.wellnessjunkiesofficial.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Shop our Amazon Store⁠⁠⁠⁠⁠Say hi: ⁠⁠⁠⁠⁠⁠⁠⁠⁠press@wellnessjunkiesofficial.com⁠⁠Please subscribe, rate, review + share to help us grow the community

We love to hear from our listeners. Send us a message.Episode 115 of Cell & Gene: The Podcast features Host Erin Harris' talk with Aliya Omer, Vice President and Global Head of Hematology and Cell Therapy at AstraZeneca. Omer shares valuable insights from her rich experience leading cell therapy development across multiple top companies. She highlights the critical importance of collaboration by breaking down silos across research, manufacturing, regulatory, and commercial teams to deliver innovative therapies efficiently. She also discusses AZ's diverse and ambitious cell therapy portfolio, encompassing autologous CAR-T, TCR-T, in vivo gene therapies, and regulatory T-cell therapies. She candidly addresses current challenges in manufacturing scalability, patient access, and healthcare system readiness and describes how AZ is prioritizing fast manufacturing platforms and ecosystem-wide partnerships to surmount these hurdles. Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Dr. Monty Pal and Dr. Pauline Funchain discuss the latest efforts to diagnose, prevent, and treat the series of immune-related adverse events that have emerged in the era of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I am Monty Pal, a medical oncologist, professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles, California. Now, it is probably no surprise to this audience that immunotherapy has transformed the treatment landscape for multiple cancer types. It remains a pillar of modern oncology. Having said that, I think we have all been baffled by certain toxicities that we run into in the clinic. Today, I am delighted to be joined by Dr Pauline Funchain to discuss some of the checkpoint inhibitor toxicities that people struggle with most. And we will also touch on some side effects of immunotherapy beyond checkpoint inhibitors: CAR-T cells, bispecifics, so on and so forth. Dr Funchain is a dear friend, and she is an associate professor and associate director of cancer research training and education at the Stanford Cancer Institute. She is co-director of the Immunotherapy Toxicity Program and the Skin Cancer Genomics Program at Stanford, where she also serves as associate program director of hematology and oncology fellowship. Dr. Funchain is also the co-founder of ASPIRE, and we are going to talk about that a little bit today, the Alliance for the Support and Prevention of Immune-Related Events. FYI for listeners, if you are interested in our disclosures, they are available at the transcript of this episode. Pauline, thanks so much for joining us today. Dr. Pauline Funchain: Monty, thank you for this invitation. It is always great to talk. Dr. Monty Pal: So, for the audience, Pauline and I know each other from my days as a fellow at City of Hope. She was a resident at Harbor UCLA and a stellar resident at that. It has just been amazing to sort of see your career grow and blossom and to witness all the cool things that you are doing. ASPIRE, in particular, sort of caught my eye. So again, for listeners, this is the Alliance for the Support and Prevention of Immune-Related Events. Can you tell us a little bit briefly about the genesis of that, how that came about? Dr. Pauline Funchain: So, there was a bunch of us who were really struggling, I mean, all of us have struggled with these immune-related adverse events, these irAEs. You know, they are new disease states, and even though they look like autoimmune diseases, they tend to need a whole lot more steroid than autoimmune diseases do and they do not totally present in the same way. And in fact, you know, Triple-M, or Triple-M overlap syndrome, is a completely new irAE, a new immune state that we have never had before the advent of checkpoint inhibitor. And so a Triple-M, for those of you who are not as familiar, that is the constellation of myocarditis, myositis, and myasthenia gravis, something that never occurs as a natural autoimmune disease. So we were starting to realize that there were some major differences with these irAEs and autoimmune diseases. We could not treat them the right way. We really needed to learn more about them. And a bunch of us who had interest in this said, "Look, we really need to be all in one space to talk about what we are doing," because all of our treatments were our own little homegrown brews, and we needed to really get together and understand how to treat these things, how to diagnose them, and then learn more about them. So, Dr. Alexa Meara from Ohio State, Dr. Kerry Reynolds from Mass Gen, we put together this research consortium, brought together all of our irAE friends, got our best subspecialists together in a research consortium, which is now only about a year and a half old. And we made this research consortium, the Alliance for Support of Prevention of Immune-Related Events, and we reached out to ASCO, and ASCO was so kind to grant us a [Alliance for Support and Prevention of Immune-Related adverse Events (ASPIRE)] Community of Practice. So we met for the first time as a Community of Practice at the ASCO Annual Meeting just this past June and really got an ASCO community together to really think about how to again, diagnose, prevent, treat irAEs. Dr Monty Pal: This is interesting to me. The ASCO Community of Practice phenomenon is something that I was not super familiar with. Can you explain to our listenership what is the ASCO Community of Practice model? If you have particular interests, how do you sort of get one started? Dr Pauline Funchain: Yeah, so ASCO has an entire page on their Community of Practice. There are multiple Community of Practice groups or COPs. There are ones for Supportive Oncology and Survivorship. There is Women in Oncology. There is a group for International Medical Graduates. And there is about, I think 10 or 12 now that have a physical presence at ASCO but also a virtual presence on the ASCO Community of Practice site. So, if you were interested in any one of these, and you can see them on the ASCO Communities of Practice sites, you would ask to become a member. Once granted membership, then there is a whole webpage of postings and conversations that people can have. You can get email digests of conversations that happen on the website, and then you can anchor it with in-person participation at the Annual Meeting. Dr Monty Pal: That is awesome, and I can think of so many different foci within oncology that really sort of deserve a Community of Practice. This definitely being one of them. You know, it strikes me as being so interesting. I mean, the checkpoint inhibitors have been around for a while now. I think when you and I were in training, gosh, back then, these were just a little bit of a pipe dream, right? But having said that, I would probably say that more than half of my kidney cancer practice is either on checkpoint inhibitors, and the vast majority have been on one at some point in their past, right? With that in mind, you know, we have all treated a lot of patients with these drugs. Why is it that we still struggle to manage the toxicities? And just to take that one step further, what are some of the toxicities that, perhaps through ASPIRE or through your experience, people struggle with the most? Dr Pauline Funchain: So, I think we are still struggling with these because again, they are new disease states, right? This is what we all experienced with COVID, a brand-new virus and a brand-new syndrome. We now have 20-plus of these as irAEs. And what we have realized about them is the immune activation that happens with these is so much more than what we have seen with autoimmune diseases. So for instance, if you have a Crohn's or ulcerative colitis, you will top out at 40 to 60 milligrams of prednisone if a Crohn's flare or ulcerative colitis flare happens. But for our severe IR colitises, you know, it is at least 1 mg per kg, often goes up to 2 mg per kg. We, in some cases, have done 1 gram pulses if we are worried that somebody is going to perforate. So that was sort of like the first 5 years of treating irAE, and then now in the sort of second 5 years of treating irAE, we have realized that that is a lot of immunosuppression, and we might be able to get away with less with the newer biologics that are on board. So, we are struggling to try to get the data for some of these irAEs that we knew, we have known for a while, but to try to get newer treatments that may immunosuppress less so that you may still be able to retain that tumor response. And in fact, some of the preclinical studies suggest that some of these biologics may actually synergize with the immunotherapy and actually make the immunotherapy more effective from a tumor perspective and calm down the irAE as sort of the bystander effect. So we are still trying to optimize those. Getting up trials in the space has been very difficult. That is one of the reasons for the genesis of ASPIRE because we realized we needed to band together to have a bigger voice in that realm. Then there are other things that are brand new. So we talked about Triple-M. So Triple-M, again, with Triple-M or any myocarditis or myasthenia, I mean, there is about a 50% chance of death from irAE based on the literature. I think we are getting better at recognizing this, and so at Stanford we have some data to say that if you serially follow troponin, that maybe your outcomes are better. You can potentially lower the percentage of cases that are fatal because you can catch them early. I mean, this is all preliminary data, but again, these are all things that are evolving, and we do not all have the right answer. I mean, even the serial troponin thing, I think, is pretty controversial. And in fact, at one of our quarterly Zoom meetings that we are doing in ASPIRE in December is going to sort of flush out that controversy about serial troponin measuring and what is the best thing to use? Would you use something like abatacept or would you use ruxolitinib? Which one is better? I think there is a lot of controversy still about these things. Dr Monty Pal: You have really piqued my curiosity here because you think about the cons of treating irAEs, right? And I worry exactly about what you had mentioned, right, which is, "Gosh, what is going on with this tumor in terms of immunosuppression?" But you think about some of the newer agents, you mentioned ruxolitinib, I have heard of dasatinib, for instance, in this setting. Frankly speaking, a lot of these, as you point out, are really thought of as being also anticancer drugs. So you have really got me thinking about the potential synergy between perhaps suppressing an irAE and augmenting antitumor activity, which I think is very interesting. Am I on the right track with that? Dr Pauline Funchain: I think so, but you will find that a lot of people will not even go there because they are worried about how much immunosuppression you are going to cause. I am at heart a geneticist, but I think an immunologist will happily tell you that the immune system is very complex. There are multiple pathways, and these drugs do not all target the same immune pathways. So if we understand a little bit more about the pathways we are targeting and pick apart the pathways that are really, really tumor relevant and the other pathways that are not tumor relevant, you may be able to piece together a better marriage of tumor response and irAE control. Dr Monty Pal: Kind of on this topic, and again, leaning on your background in genetics, where are we in terms of predicting these irAEs? I mean, you would think the holy grail would be picking out a snip or something of this for it, right, that could potentially identify that patient who is going to get Triple-M or, you know, at the very least a significant high-grade irAE event. Are we anywhere closer to that in 2025? Dr Pauline Funchain: There have been data published. There have been some big GWAS studies. All of the effect sizes are pretty small. So there are some prediction algorithms, but none of them are clinically useful. And I think when you look at the odds ratios, they will increase risk by maybe 20%. I think one of the things that we found in a very small series and supported anecdotally is something as easy as family history of autoimmune disease is probably more predictive at this point than any of those types of markers. I think we will get there, but we are not anywhere near where we would like to be. Things like TMB also, actually, there is some good data about higher TMB, higher risk of irAE too. Dr Monty Pal: Interesting. I see all this data coming through, IL-8 polymorphisms, etc. And I just wondered if any of that was ready for prime time. But I mean, this is a good message for the practicing clinician. Sounds like we are not quite there yet. And I could probably keep you on for another entire podcast to talk about this topic, but let us see if we can at least skim the surface. I never thought I would see the day when BiTEs and CAR-Ts were entering into my kidney cancer practice, but in fact, it is really become central to a lot of our clinical trials in RCC these days. I would be lying if I did not say that I was not struggling with the toxicities and so forth associated with these drugs. Can you give us a quick primer, maybe just good resources that people can go to for managing toxicity with BiTEs and with CAR and with some of these novel therapeutic modalities that we are using in the oncology clinics? Dr Pauline Funchain: I know there is a recently published toxicity manual for BiTEs in hematologic malignancies, I think it was in Blood. CAR-T is covered in many irAE guidelines. So ASCO guidelines actually has a CAR-T [cell therapy guideline], and I would be remiss not to point out that actually ASCO has a, I am a little biased, but a wonderful guideline on irAE that is actually being updated as we speak. We are hoping for publication next year. I find the format of that, there are many guidelines out there, actually. There is ASCO, SITC, ESMO has a guideline for irAE, but I find the formatting of the ASCO guideline to be much easier to flip through during clinic, just because of the visual format of the tables. But that is going to be updated next year. And with CAR-T, there is now multiple publications also in terms of guidelines. But what I will say about bispecifics and CAR-T, so they have very similar toxicities in terms of the cytokine release and also with the ICANS, so the neurotoxicity. But what we have been finding that is really interesting with BiTEs and CAR-T, and actually even with TIL, cytokine release is very similar to some of the IL-2 toxicities but not identical that we see with TIL treatment. But now we are starting to see overlap. So patients who have been treated with immunotherapy and then go on to get a bispecific or then go on to get TIL, so I have seen some colitises that have occurred after the fact. Some of the newer CAR-Ts without checkpoint have been causing some really interesting, probably not in a good way, but interesting biologically, colitises that are really refractory. So we are starting to see some overlap, and again, I think this field is just evolving constantly. Dr Monty Pal: Yeah, no, I almost think I need to go back to that fellowship that you and I did together 20 years ago and, you know, and see if I could repeat some coursework on CAR-T management.  You know, Pauline, I could probably keep you on the horn for hours, but this has just been terrific. Thank you so much for sharing all of your insights with us today on the ASCO Daily News Podcast. Dr Pauline Funchain: Thank you for the invitation. It was wonderful to talk about this, and it was wonderful to catch up a little bit, Monty. Dr Monty Pal: Same here, same here. And thanks to our listeners too. If you value the insights you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:      Dr. Monty Pal    @montypal   Dr. Pauline Funchain @FunchainMD Follow ASCO on social media:       @ASCO on Twitter      ASCO on Bluesky     ASCO on Facebook       ASCO on LinkedIn     Disclosures: Dr. Monty Pal:     Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview    Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical    Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis    Dr. Pauline Funchain: Consulting or Advisory Role: Merck, Replimune, Sanofi/Regeneron, Immunocore, Tempus Research Funding (Inst.): Pfizer, Bristol-Myers Squibb, IDEAYA Biosciences, Linnaeus Therapeutics Travel, Accommodations, Expenses: Merck

In this value-packed episode, e-commerce expert Matthew Stafford shares how understanding and responding to real customer data powers dramatic business growth and website conversion lifts. Matthew describes his journey from ad specialist to conversion optimization guru—driven by necessity, continuous learning, and a genuine passion for data-driven problem-solving. Together with Jeff Mains, they dive into practical strategies for removing friction from your site, the science of micro-commitments, actionable post-purchase surveys, and how to build websites that truly speak to your ideal customers. Whether you're in SaaS or e-commerce, this episode delivers actionable steps to boost conversions, collect meaningful insights, and lead your team to sustained success.Key TakeawaysThe Power of Website Data (00:00:00)Deeply understanding what users actually do on your site beats guessing or bias. Data is “agnostic” and reflects real user behavior.Solve the Right Problems with Data-Driven Insights (00:01:05)Tracking analytics turned Matthew's declining sales around from loss to profitability.Post-Purchase Surveys Drive Revenue (00:05:01)Implement a simple post-purchase question: “What almost stopped you from buying?” The answers lead to multi-million dollar wins.Micro-Commitments & Button Text (00:13:11)“Buy now” creates friction. Instead, use action-specific steps like “Add to Cart” or “Learn More” to lead customers smoothly to purchase.Focus on Simplicity & Clarity (00:10:43)Clarity always trumps persuasion. Present the next necessary action clearly and reduce choices to avoid customer confusion.Start Optimization at the Checkout, Work Backwards (00:27:51)Always optimize conversion pages (checkout, cart, product page) before iterating on the homepage or filters.Tweetable Quotes"The data is agnostic. It doesn't care what you're thinking—it just tells you exactly what they're doing." —Matthew Stafford"Clarity trumps persuasion. Make your site so simple that Homer Simpson would understand it." —Matthew Stafford"If you describe the problem better than your customer can, they'll assume you have the solution." —Matthew Stafford"Stop treating customers like transactions. Treat them like your mom—build real relationships." —Matthew Stafford"People don't want to click on a button if they don't know where it's taking them. Make every step clear." —Matthew Stafford"You don't have a brand until you can stop running ads and survive. Until then, you just have a good funnel." —Matthew StaffordSaaS Leadership LessonsBe Willing to Learn Before DelegatingMatthew learned analytics himself before hiring, allowing him to hire better and direct vision with confidence.Let Data Be Your GuideRemove ego and personal preference; let unbiased customer data inform and drive your decisions.Prioritize Problems with Greatest Revenue ImpactStart optimization where money changes hands, not where you “feel” the problem is.Don't Redesign for VanityAvoid unnecessary redesigns driven by boredom or internal desire for novelty; new visitors see your site for the first time.Embrace Customer ConversationsReal feedback, surveys, and live chats are goldmines for improvement and repeat sales.Iterate with Focused ExperimentsTest, don't guess: collect feedback, run tests on focused elements, and double down on what specifically works.Guest...

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Download the transcript here

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Listen to the podcast here

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-cell lymphoma in a study with 245 patients. Findings show a tentative way forward in treatment for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Featured Article:Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Revolutionizing Retail: Drew Ann Long's Caroline's Cart Journey In this episode of 'Why Not Me', hosted by Tony Mantor from Nashville, Tennessee Drew Ann Long shares her inspiring story of creating Caroline's Cart—a revolutionary shopping cart designed for individuals with special needs. Drew Ann, motivated by her daughter Caroline's severe disabilities, overcame numerous challenges, financial hurdles, and industry skepticism to bring her vision to life. Despite initial rejections from manufacturers, Drew's relentless pursuit led to global recognition and adoption of Caroline's Cart, transforming accessibility in retail. She also discusses the formation of Caroline's Cause, a nonprofit providing scholarships to families with special needs children. Drew's journey highlights the impact of empathy-driven innovation and the importance of taking bold risks to make a difference. Meet Drew Ann Long: Founder of Caroline's Cart The Birth of Caroline's Cart Challenges and Breakthroughs The First Prototype and Social Media Explosion Manufacturing Struggles and Success Nationwide and International Expansion Caroline's Cause: Giving Back Future Plans and Continued Growth Closing Thoughts and Contact Information Music written By T. Wild Mantor Music BMI The content on Why Not Me: Embracing Autism amd Mental Health Worldwide, including discussions on mental health, autism, and related topics, is provided for informational and entertainment purposes only. The views and opinions expressed by guests are their own and do not reflect those of the podcast, its hosts, or affiliates.Why Not Me is not a medical or mental health professional and does not endorse or verify the accuracy, efficacy, safety of any treatments, programs, or advice discussed.Listeners should consult qualified healthcare professionals, such as licensed therapists, psychologists, or physicians, before making decisions about mental health or autism- related care.Reliance on this podcast's contents is at the listener's own risk. Why Not Me is not liable for any outcomes, financial or otherwise, resulting from actions taken based on the information provided. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

Federico Cartín es director ejecutivo de la asociación Costa Rica por Siempre, una organización privada sin fines de lucro que busca proteger los ecosistemas marinos y terrestres a través de la gestión de fondos y alianzas con gobiernos, el sector privado y la sociedad civil  En este episodio, Federico conversó con la profesora Andrea Prado acerca de los fondos de conservación en Costa Rica, así como del impacto y potencial que tiene la economía azul para nuestra región. El podcast Gerente de Impacto es dirigido por la Prof. Andrea Prado y producido por la Cátedra Strachan de INCAE Business SchoolEscúchelo en: 

Ecoutez L'édito d'Etienne Gernelle du 04 novembre 2025.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

From checkout to cart to the Customer Portal, this release streamlines the buyer journey and gives you more control behind the scenes. Think fewer upgrade headaches, cleaner customer touchpoints, and...

Arlette Chabot a écouté toutes les déclarations de Marine Le Pen, de Jordan Bardella sur les débats budgétaires, sur les impôts, sur les taxes et sur la dépense publique. C'était difficile à suivre ces derniers temps. Elle dit que c'est un grand écart, on a du mal à se retrouver. Pour Dominique Seux, il y a des exemples qui montrent que les taxes ont des incidences économiques, voire industrielles, c'est l'aviation d'affaires. Ce n'est pas que le secteur ne l'intéresse pas en tant que tel, mais c'est un enseignement qui montre que les meilleures intentions du monde peuvent aboutir à une catastrophe. Celui que l'on appelait le vice-président le plus détesté de l'histoire américaine est l'exemple le plus spectaculaire de ce que la morale peut faire comme ravage. Selon Abnousse Shalmani, Dick Cheney est devenu un symbole d'intégrité loué par les démocrates, tout simplement parce qu'à la fin de sa vie, il s'est prononcé contre Donald Trump. Du lundi au vendredi, à partir de 18h, David Pujadas apporte toute son expertise pour analyser l'actualité du jour avec pédagogie.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Sánchez comparece en el Senado y califica la comisión de circo, evadiendo preguntas clave con un recurrente "no me consta". Se le acusa de encenagamiento político y de no ofrecer explicaciones convincentes sobre su presunta implicación en casos de corrupción. En Pamplona, cuatro argelinos son detenidos por agresión sexual y robo. El embajador de Japón en España, Takahiro Nakamae, finaliza su misión, siendo reconocido por su dedicación al país. Se analiza que Sánchez sale vivo de la comparecencia, pero acorralado y sin ofrecer claridad. La inflación se dispara, afectando la luz, viajes y billetes de tren. En deportes, se juega la Copa del Rey y la Liga. A nivel internacional, Trump anuncia la reanudación de pruebas nucleares y se observa un deshielo comercial entre EE.UU. y China. El Hospital de La Paz presenta una terapia pionera con células CAR-T para la leucemia infantil, logrando resultados esperanzadores. COPE informa sobre la agenda de Madrid, incluyendo un dispositivo de ...

-SNAP benefits are running out due to the Schumer Shutdown, and Rob suggests giving to your local food bank — or preparing to ankle-tackle grocery thieves like a patriotic linebacker. -Between rants about the bourgeoisie, fentanyl, and golf carts, Rob declares the Democrat Party dead, buried, and possibly returning as a zombie by the midterms. Today's podcast is sponsored by : BEAM DREAM POWDER : Improve your health by improving your sleep! Get 40% off by using code NEWSMAX at http://shopbeam.com/NewsmaxGET FRESH OLIVE OIL : Try real farm fresh olive oils for FREE plus $1 dollar shipping at http://GetFreshRobCarson.comBIRCH GOLD - Protect and grow your retirement savings with gold. Text ROB to 98 98 98 for your FREE information kit! To call in and speak with Rob Carson live on the show, dial 1-800-922-6680 between the hours of 12 Noon and 3:00 pm Eastern Time Monday through Friday…E-mail Rob Carson at : RobCarsonShow@gmail.com Musical parodies provided by Jim Gossett (www.patreon.com/JimGossettComedy) Listen to Newsmax LIVE and see our entire podcast lineup at http://Newsmax.com/Listen Make the switch to NEWSMAX today! Get your 15 day free trial of NEWSMAX+ at http://NewsmaxPlus.com Looking for NEWSMAX caps, tees, mugs & more? Check out the Newsmax merchandise shop at : http://nws.mx/shop Follow NEWSMAX on Social Media:  -Facebook: http://nws.mx/FB  -X/Twitter: http://nws.mx/twitter -Instagram: http://nws.mx/IG -YouTube: https://youtube.com/NewsmaxTV -Rumble: https://rumble.com/c/NewsmaxTV -TRUTH Social: https://truthsocial.com/@NEWSMAX -GETTR: https://gettr.com/user/newsmax -Threads: http://threads.net/@NEWSMAX  -Telegram: http://t.me/newsmax  -BlueSky: https://bsky.app/profile/newsmax.com -Parler: http://app.parler.com/newsmax Learn more about your ad choices. Visit megaphone.fm/adchoices

Pedro Sánchez comparece en la comisión de investigación del Senado, donde el PP critica su actitud evasiva y su falta de colaboración. Sánchez acusa a la ultraderecha de atacar a las mujeres. Se analizan las consecuencias de esta comparecencia, con los aliados de Sánchez considerando que sale "indemne" y la oposición pidiendo su dimisión. Carlos Mazón, presidente de la Generalitat Valenciana, reflexiona sobre un evento pasado que genera más peticiones de dimisión. En noticias internacionales, se informa sobre un acuerdo entre Trump y Xi, la entrega de cuerpos por parte de Hamás, ataques rusos a Ucrania y detenciones por el robo del Louvre. A nivel nacional, cuatro detenidos por agresión sexual en Pamplona ingresan en prisión. La inflación de octubre sube al 3.1%. Se informan de complicaciones de tráfico en Madrid. El Hospital de la Paz anuncia un avance con células CAR-T en niños con leucemia. Miguel Tellado del PP critica duramente a Sánchez y su gobierno, afirmando que está ...

In this Review Series episode, Associate Editor Dr. Philippe Armand speaks with multiple authors about what it might look like to improve treatments follicular lymphoma, a disease that has been put on the backburner of innovation due to its generally treatable nature. Dr. Armand discusses "Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?" with author Dr. Carla Casulo,  "The future of follicular lymphoma management: strategies on the horizon” with author Dr. Sarah C. Rutherford, and "An updated understanding of follicular lymphoma transformation” with Dr. Erin M. Parry.Find the whole review series on follicular lymphoma in volume 146 issue 15 of Blood Journal.  

In this episode, we dive into how to run the best promotions for Black Friday and Cyber Monday (BFCM). Nathan Ho, Product Manager of EasyGift, shares his experience and advice on structuring promotions, using tiered spending to increase average order value, and the power of free gifts. He also discusses different marketing strategies like scheduled rules and audience targeting to maximize sales during the busiest shopping days.Topics discussed in this episode:  How to start preparing for Black Friday as early as possible.What tiered minimum spend promotions are and why they work.Why a free gift is a strong trigger to encourage customers to buy more.How to use gifts as product samples to introduce new items.What scheduled rules are for setting time-specific deals.How to simplify promotions to avoid confusing your customers.What the classic promotion triggers are: cart value, products, and collections.How to use magic links to target new customers from ads.Why testing promotions before launch is critical to avoid conflicts.What optimizing shipping can do to stand out from competitors.Links & Resources Website: https://www.506.io/easygiftShopify App Store: https://apps.shopify.com/gifter-cart-auto-includeLinkedIn: https://www.linkedin.com/company/506-io/X/Twitter: https://twitter.com/506_appsGet access to more free resources by visiting the show notes at https://tinyurl.com/ab8jb8p3______________________________________________________ LOVE THE SHOW? HERE ARE THE NEXT STEPS! Follow the podcast to get every bonus episode. Tap follow now and don't miss out! Rate & Review: Help others discover the show by rating the show on Apple Podcasts at https://tinyurl.com/ecb-apple-podcasts Join our Free Newsletter: https://newsletter.ecommercecoffeebreak.com/ Support The Show On Patreon: https://www.patreon.com/EcommerceCoffeeBreak Partner with us: https://ecommercecoffeebreak.com/partner-with-us/

This week Emily gets artsy over the man behind CARTdepartment.         SHOW NOTES: Larry Warsh interview Jay Z, Kanye West Otis music video Lots of CART car pics  @cartdept Recorded, edited & mixed by Emdognightmare & Queen of the Vans Production & research Queen of the Vans & Emdognightmare Find us: Car Krush Stay updated w/ our newsletter Hugs, thank you & high fives to Greg Meleney for the killer tunez!

durée : 00:05:32 - Le Billet politique - par : Stéphane Robert - Le Premier ministre, Sébastien Lecornu, estime qu'il n'a plus besoin du Sénat pour élaborer et faire adopter le budget de l'année prochaine. Il fait désormais le pari qu'il peut trouver une majorité à l'Assemblée nationale.

This month, the gals are joined by Trevin from Live, Laugh, Larceny Podcast to discuss a wiener catastrophe, poop spray damage, Sierra's stains, litter at the country club, a food critic for the people, and the most accident-prone pastor you've ever heard of. Tune in for October's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

Radio Foot à 16h10-21h10 T.U. à la Une ce lundi : - Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! ; - Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! Un an et demi de disette pour les Blancos, une première référence pour les Merengue et Xabi Alonso. Sans Raphinha ni Lewandowski, l'homme en forme des Blaugranas, Fermin Lopez, a permis aux Catalans de revenir. Mbappé décisif, même si le Kyks a vu Szczesny stopper sa tentative de penalty. Le but refusé de la 12è minute. Une célébration de courte durée. La frustration du hors-jeu semi-automatique ? Autre frustration, celle de Vinicius Jr, remplacé par Rodrygo à 20 minutes de la fin. - Lamine Yamal bien muselé par Alvaro Carreras, une fin de match sous tension. Le Real en profite pour se détacher, compte 5 points d'avance sur son rival catalan.   Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? L'OM s'était installé dans le fauteuil de leader, mais encaisse une 2è défaite d'affilée. Après la déconvenue du Sporting en C1, les Phocéens battus à Lens. Ils n'auront gardé l'avantage que 7 minutes. Nouvelle soirée de cauchemar pour Benjamin Pavard, après celle de Lisbonne mercredi dernier. On n'arrête plus les Sang et Or de Pierre Sage, qui s'emparent de la 2è place, la 10è journée se joue mercredi. Pour débattre avec Hugo Moissonnier, Manu Terradillos, Hervé Penot et Dominique Sévérac. Technique/réalisation : Laurent Salerno - Pierre Guérin.

Radio Foot à 16h10-21h10 T.U. à la Une ce lundi : - Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! ; - Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! Un an et demi de disette pour les Blancos, une première référence pour les Merengue et Xabi Alonso. Sans Raphinha ni Lewandowski, l'homme en forme des Blaugranas, Fermin Lopez, a permis aux Catalans de revenir. Mbappé décisif, même si le Kyks a vu Szczesny stopper sa tentative de penalty. Le but refusé de la 12è minute. Une célébration de courte durée. La frustration du hors-jeu semi-automatique ? Autre frustration, celle de Vinicius Jr, remplacé par Rodrygo à 20 minutes de la fin. - Lamine Yamal bien muselé par Alvaro Carreras, une fin de match sous tension. Le Real en profite pour se détacher, compte 5 points d'avance sur son rival catalan.   Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? L'OM s'était installé dans le fauteuil de leader, mais encaisse une 2è défaite d'affilée. Après la déconvenue du Sporting en C1, les Phocéens battus à Lens. Ils n'auront gardé l'avantage que 7 minutes. Nouvelle soirée de cauchemar pour Benjamin Pavard, après celle de Lisbonne mercredi dernier. On n'arrête plus les Sang et Or de Pierre Sage, qui s'emparent de la 2è place, la 10è journée se joue mercredi. Pour débattre avec Hugo Moissonnier, Manu Terradillos, Hervé Penot et Dominique Sévérac. Technique/réalisation : Laurent Salerno - Pierre Guérin.

In this episode, I'm joined by Dr. Burhan Chaudhry, MS neurologist and clinical lead at Bristol Myers Squibb, to discuss CAR-T cell therapy which is an innovative treatment currently enrolling in clinical trials for multiple sclerosis (MS). We dive into how CAR-T cell therapy targets B cells within the central nervous system, offering hope for both relapsing and progressive MS. Dr. Chaudhry explains what sets CAR-T apart from traditional disease modifying therapies, how to get involved in MS clinical trials, and what participants can expect throughout the process. Whether you're newly diagnosed or living with MS for years, join us for empowering strategies, expert advice, and the latest updates on breakthroughs in MS treatment! Bio on Burhan Chaudry: Dr. Burhan Chaudhry is a MS neurologist and clinical lead at Bristol Myers Squibb. His sister was diagnosed with MS when he was in medical school. This inspired him to pursue Neurology. A few years after Burhan was diagnosed with MS as well. After becoming a MS neurologist, Burhan has treated MS patients both in the US and internationally. He is currently clinical lead for a global clinical trial evaluating a novel cell therapy across the MS spectrum. Resources mentioned in this episode: Website to view CAR-T info: https://www.cartautoimmune.com/ ECTRIMS 2025 Results/Report: https://distribute.congrex.com/from.storage?image=rqetJOF1YXChDh_STAPoNpjPhysyG76sohBKnHJhR-TsF3Mvxzx13zdmic5t9umH0 Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

Just about a month ago, 9,600 researchers, clinicians, and representatives from patient advocacy organizations gathered in Barcelona for the European Committee on Treatment and Research in MS annual scientific congress, better known as ECTRIMS, the largest MS research conference in the world. Now that he's had an opportunity to review his notes and digest all of the science presented at ECTRIMS 2025, Dr. Bruce Bebo, the National MS Society's Executive Vice-President of Research, returns to the podcast to take us on a deep dive covering some of the most important research presented this year. We're also talking about next-generation CAR T-cell therapy for MS, and we'll explain why it's such exciting news. We're sharing details about a DNA-based therapy for overactive bladder that just received fast-track status from the FDA. We'll tell you about a new effort to develop a simple blood test that will detect MS progression. We have some news to share about the RealTalk MS app. And we want to remind you to check out our ECTRIMS Extra Conversations video playlist on the RealTalk MS YouTube channel! We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A deep dive into the research presented at ECTRIMS 2025  :22 Kernal Biologics received $48 million grant for the next-generation CAR T-Cell therapy  2:35 FDA grants fast track designation to DNA-based therapy to treat overactive bladder  6:02 Octave Bioscience receives grant to develop a blood test to detect MS progression  8:30 News about our app  9:42 Have you checked out our ECTRIMS Extra Conversations YouTube playlist?  10:30 Dr. Bruce Bebo discusses some of the most important research presented at ECTRIMS 2025  11:06 Share this episode  32:26 Next week's episode  32:47 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/425 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy LISTEN: RealTalk MS Ep 422: From ECTRIMS 2025 with Dr. Bruce Bebo and Kristine Werner Ozug https://realtalkms.com/422 WATCH: The RealTalk MS ECTRIMS Extra Conversations video playlist on YouTube https://realtalkms.com/ectrims2025 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms DOWNLOAD: The RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 DOWNLOAD: The RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 425 Guests: Dr. Bruce Bebo Privacy Policy

Hello my lovelies and welcome back to another episode of the pod, and another human being who changing the world! This time I am introducing you to Drew Ann Long, change-maker, world-builder and someone who does not believe in the word "NO", especially when one is trying to make this world better, and shinier, for everyone else! Drew is someone who believes deeply in the goodness in others, in her capacity for showing up for others, and oh, yeah, NEVER GIVING UP! To read about Drew and Caroline's Cart, and Caroline's Cause, click here! To connect with her on Facebook, click here! Do yourself a favor, inspire yourself and remember, that each an every one of us has the ability to do BIG THINGS!! Be like Drew, in other words! PLEASE REMEMBER TO RATE AND REVIEW. IT'S A BIG DEAL AND MEANS SO MUCH TO ME! Your bit of beauty is this: this sweet and powerful YouTube video detailing her journey and her refusal to ever give up!

Hello my lovelies and welcome back to another episode of the pod, and another human being who changing the world! This time I am introducing you to Drew Ann Long, change-maker, world-builder and someone who does not believe in the word "NO", especially when one is trying to make this world better, and shinier, for everyone else! Drew is someone who believes deeply in the goodness in others, in her capacity for showing up for others, and oh, yeah, NEVER GIVING UP! To read about Drew and Caroline's Cart, and Caroline's Cause, click here!  To connect with her on Facebook, click here! Do yourself a favor, inspire yourself and remember, that each an every one of us has the ability to do BIG THINGS!! Be like Drew, in other words! PLEASE REMEMBER TO RATE AND REVIEW. IT'S A BIG DEAL AND MEANS SO MUCH TO ME! Your bit of beauty is this: this sweet and powerful YouTube video detailing her journey and her refusal to ever give up!

On today episode, Andy & DJ discuss ICE rolling Portland protester away on flatbed cart as Trump says city is burning to the ground, a bloody Mark Sanchez seen stumbling down Indianapolis sidewalk after being stabbed in fight with grease truck driver, and a brand new segment of AI or Nah.